Table 3. Summary of findings: Benznidazole versus placebo.
| Outcome | Absolute effects (95% CI) | Relative effect (95% CI) | № of participants (studies) |
Certainty of the evidence | |
|---|---|---|---|---|---|
| Risk with placebo: efficacy | Risk with benznidazole | ||||
| Positive PCR | 883 per 1.000 |
150 per 1.000 (88 to 265) |
RR 0.20 (0.16 to 0.25) |
152 (2 RCTs) |
⨁⨁⨁⨁ HIGH |
| - Fixed dose 300 mg/day for 14 to 56 days | 833 per 1.000 |
100 per 1.000 (33 to 300) |
RR 0.12 (0.04 to 0.36) |
60 (1 RCT) |
⨁⨁⨁⨁ HIGH |
| - Adjusted dose | 915 per 1.000 |
174 per 1.000 (91 to 339) |
RR 0.19 (0.10 to 0.37) |
92 (1 RCT) |
⨁⨁⨁⨁ HIGH |
| Drug discontinuation | 24 per 1.000 |
181 per 1.000 (61 to 533) |
RR 7.42 (2.51 to 21.91) |
846 (3 RCTs) |
⨁⨁⨁⨁ HIGH |
| - Fixed dose | 33 per 1.000 |
333 per 1.000 (45 to 1.000) |
RR 10.00 (1.36 to 73.33) |
60 (1 RCT) |
⨁⨁⨁⨁ HIGH |
| - Adjusted dose | 24 per 1.000 |
150 per 1.000 (30 to 753) |
RR 6.35 (1.27 to 31.86) |
786 (2 RCTs) |
⨁⨁⨁⨁ HIGH |
| Peripheral neuropathy | 2 per 1000 |
10 per 1000 (2 to 47) |
RR 4.27 (0.94 to 19.40) |
919 (3 RCTs) |
⨁⨁⨁⨁ HIGH |
| - Fixed dose | 0 per 1000 |
0 per 1000 (0 to 0) |
RR 1.52 (0.16 to 14.32) |
210 (2 RCTs) |
⨁⨁⨁⨁ HIGH |
| - Adjusted dose | 3 per 1000 |
28 per 1000 (4 to 221) |
RR 10.14 (1.31 to 78.81) |
709 (1 RCT) |
⨁⨁⨁⨁ HIGH |
| Mild rash | 67 per 1000 |
357 per 1000 (246 to 520) |
RR 5.32 (3.66 to 7.74) |
919 (3 RCTs) |
⨁⨁⨁⨁ HIGH |
| - Fixed dose | 50 per 1000 |
312 per 1000 (111 to 876) |
RR 6.24 (2.22 to 17.52) |
210 (2 RCTs) |
⨁⨁⨁⨁ HIGH |
| - Adjusted dose | 70 per 1000 |
363 per 1000 (243 to 544) |
RR 5.19 (3.47 to 7.77) |
709 (1 RCT) |
⨁⨁⨁⨁ HIGH |